A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986259 in Participants With Varying Degrees of Renal Function
Latest Information Update: 27 Sep 2021
At a glance
- Drugs FA-relaxin (Primary)
- Indications Decompensated heart failure
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 20 Sep 2021 Status changed from active, no longer recruiting to completed.
- 07 Aug 2020 Planned End Date changed from 24 Jun 2020 to 25 Feb 2021.
- 07 Aug 2020 Planned primary completion date changed from 23 Jun 2020 to 25 Feb 2021.